Merck has secured US Food and Drug Administration (FDA) Breakthrough Therapy designation for enpatoran, its investigational oral treatment for lupus with active cutaneous manifestations, marking a significant regulatory milestone for the drug candidate.
Enpatoran is a selective oral toll-like receptor (TLR) inhibitor designed to target key inflammatory pathways that drive lupus, a chronic autoimmune disease that can affect multiple organs, including the skin, joints, kidneys and central nervous system.
"For the 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden, the lack of targeted treatment makes the disease hard to control,” said David Weinreich, Global Head of R&D and CEO for the Healthcare business of Merck.
“This Breakthrough Therapy designation demonstrates that enpatoran has the potential to redefine how we approach lupus, by addressing the visible burden of rash, while potentially driving benefit beyond the skin. We look forward to working with the FDA to potentially bring this much-needed option to patients as quickly as possible.”
The designation is based on findings from the Phase 2 WILLOW trial, a multicentre, randomised, double-blind, placebo-controlled, dose-finding study evaluating the safety and efficacy of orally administered enpatoran. The innovative adaptive basket trial enrolled patients with both cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).
Results from the study showed that enpatoran produced clinically meaningful improvements in lupus symptoms, with particularly strong benefits observed in patients with active cutaneous manifestations.
Building on those findings, Merck has launched the global Phase 3 ELOWEN 1 and ELOWEN 2 studies to further assess enpatoran's effects on both cutaneous and systemic disease activity, while also exploring the relationship between skin and systemic manifestations of lupus.
